Mobia Medical's third quarter split cleanly in two. On the bottom line, the stroke-recovery device maker posted a loss of $0.52 per share, missing the consensus estimate of a $0.46 loss by 13.0%. On the top line, revenue of $15.62 million beat the $14.1 million consensus by 10.8%. Management also raised full-year 2026 revenue guidance to $57.0 million to $57.5 million, up from $54.0 million to $56.0 million. For a commercial-stage company in its second public quarter, the revenue beat and raised outlook matter far more than the per-share miss. That is the central takeaway. The central tension is that growth, while still exceptional, is clearly decelerating, and spending is rising nearly as fast as sales.

The quality of the revenue beat holds up. Revenue rose 73% from $9.0 million a year earlier and 16% sequentially from $13.5 million in the second quarter. Units climbed to about 425 from about 367. Gross margin expanded to 83.2% from 79.6% a year ago, helped by lower freight and tariff costs and fewer inventory write-offs.

The loss line is less flattering. Operating expenses jumped 71% to $31.5 million, including $2.2 million of additional stock-based compensation. Operating loss widened to $18.5 million from $11.3 million, and net loss grew to $17.3 million from $11.4 million. The dramatic year-over-year improvement in per-share loss, from $13.31 to $0.52, is an artifact of the post-IPO share count and says nothing about profitability. Sequentially, net loss did narrow from $21.0 million, but the second quarter included a roughly $4 million non-cash convertible-note mark. Operating leverage, in other words, is still more promise than evidence.

The call added texture on both sides. Management said growth came disproportionately from existing customers, a sign of deepening utilization rather than reliance purely on new territories. It also cited a hospital that expanded to a full IDN implementation after paired VNS was added to the updated AHA/ASA stroke guidelines in August. The CMS OPPS final rule confirmed the New Tech APC reimbursement treatment, which was only a proposal on the prior call, removing one overhang. Executives sounded noticeably more assertive, saying "all of the things that we thought would happen are going to happen."

Yet bears have legitimate ammunition:

• **Slowing growth.** Year-over-year revenue growth slowed from 102% in the second quarter to 73%. Active-territory growth eased from 92% to 78%, with territory additions holding at roughly 4.5 per quarter (40 average active territories versus 35.5) rather than accelerating.
• **A modest fourth-quarter outlook.** The raised guidance implies fourth-quarter revenue of roughly $15.8 million to $16.3 million. That is only modest sequential growth, and it points to a further step-down in the year-over-year rate.
• **Flat margins.** Gross margin was flat sequentially, and management's outlook remains "low 80s."
• **Cash burn.** Cash fell to $160.7 million from $177.1 million, a burn of about $16 million that included about $3.5 million of deferred IPO costs.
• **Unresolved reimbursement and disclosure gaps.** Broad payer coverage is still described as a multi-year build. There was no update on the Level 6 APC timeline, and management again declined to disclose territory productivity or mature-territory volumes.

The next major data milestone is not expected until 2027.

Investor sentiment entered the report deeply negative but less so than last quarter, improving from -1.00 to roughly -0.72. Price action tells a similar story of damaged but recovering expectations. Shares spiked to $13.52 the day after the August report, slid to a 52-week low of $8.03 on October 19, and then rebounded about 40% to $11.24 ahead of this release. That still leaves the stock 12.6% below the $12.86 opening price after the prior report and about 17% below the inter-earnings high, though it sits roughly 43% above its 200-day moving average of $7.87. Anchored VWAP readings have turned positive, consistent with the October rebound, while sequential growth trends are neutral. The market setup is more complicated than a simple miss implies: the stock has already worked through a sharp drawdown and partial recovery, so investors were likely focused on growth durability more than per-share losses.

The bottom line is that Mobia delivered what a high-growth device story needs: a solid revenue beat, a credible guidance raise, guideline inclusion and final reimbursement clarity. The EPS miss reflects heavy commercial investment rather than a demand problem. The open questions are how far year-over-year growth decelerates as comparisons toughen, and when rising operating expenses begin to translate into visible leverage. Until management provides productivity data and payer coverage broadens, the narrative remains promising but unproven, and a still-skeptical investor base will be watching the fourth-quarter growth rate closely.